Dr. Aubry Miller

The discovery of innovative cancer drugs can be realized by developing selective inhibitors of molecular drug targets and through the chemical synthesis and structural modification of natural products endowed with unique anti-tumor profiles. Central to both of these pursuits is chemical synthesis.

The strong basic research knowledge generated in the DKFZ provides novel molecular targets (e.g. cell cycle regulators and transcription factors) for oncology drug development, and Nature provides the inspiration and challenge to pursue the laboratory synthesis of natural products and natural product-inspired analogs.

Our group combines expertise in medicinal chemistry and natural product synthesis with biological testing to progress small-molecule inhibitors through the early stages of their development. Successful projects will enter clinical testing in collaboration with the National Center for Tumor Diseases or external partners.